92% of Healthcare Leaders Won't Trust AI at Scale Without Deep Clinical Expertise

This is more bearish for the sell-side healthcare AI basket than for healthcare IT broadly. The economic takeaway is that budgets are not shifting to "AI-first" vendors; they are shifting to workflow incumbents that already sit inside clinical systems and can absorb the integration burden. That favors platforms with distribution and implementation depth, while standalone AI names face longer sales cycles, lower expansion rates, and higher customer acquisition costs as pilots fail to convert into enterprise rollouts.

The immediate market reaction should be muted, but the 1-3 month catalyst is whether earnings calls show stalled expansion revenue or delayed go-lives from hospital customers. If adoption remains pilot-heavy, multiples in pure-play healthcare AI should compress as investors reprice TAM conversion and not just model quality. Over 6-18 months, the durable winner is the vendor that can be embedded in EHR workflows and monetize services, not the one with the best demo deck.

The contrarian read is that this is not a referendum on healthcare AI; it is a referendum on distribution. The survey is also self-serving, so treat it as directional rather than definitive, but the message aligns with what enterprise buyers usually do: they buy risk reduction, not novelty. The thesis is falsified if we see broad enterprise expansions, multi-department deployments, or hospital budgets explicitly reallocated toward autonomous AI rather than implementation-heavy hybrid models.